Business
Sernova Announces Peer Reviewed Publication Demonstrating Positive Preclinical Safety and Efficacy Indicators of Its Novel Cell Pouch System(TM) Therapeutic Approach for Treatment of Thyroid Disease
(TheNewswire) Sernova prepares for clinical trial of new treatment for post-o...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces Peer Reviewed Publication Demonstrating Positive Preclinical Safety and Efficacy Indicators of Its Novel Cell Pouch System(TM) Therapeutic Approach for Treatment of Thyroid Disease\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Sernova prepares for clinical trial\nof new treatment for post-operative hypothyroidism\n \n \n \n \n LONDON, ONTARIO -\n \n \n TheNewswire\n \n \n – January 27, 2022 –\nSernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage\nregenerative medicine and cell therapy therapeutics company developing\na potential ‘functional cure’ for chronic diseases including type\n1 diabetes (T1D) is pleased to announce publication of a peer reviewed\npreclinical study demonstrating positive results of a novel Cell Pouch\nSystem™ cell therapy approach to treat hypothyroidism and\npotentially avoid lifelong dependence on thyroid medication following\nsurgical removal of the thyroid gland.\n \n \n \n \n The journal article entitled\n \n \n “\n \n \n \n \n Subcutaneous transplantation of human thyroid tissue into a\npre-vascularized Cell Pouch™ device in a Mus musculus model:\nEvidence of viability and function for thyroid\ntransplantation\n \n \n \n \n ,”\n \n \n by lead author, Dr. Sam M. Wiseman was\npublished in the prestigious scientific journal,\n \n \n PLOS ONE\n \n \n , January\n20, 2022.\n \n \n In this study, thyroid tissue from\npatients undergoing surgery for treatment of benign disease was\ntransplanted into Sernova Cell Pouches that had been previously\nimplanted into laboratory mice. The aim of the study was to\ninvestigate the long-term survival of human thyroid tissue in the Cell\nPouch and evaluate the ability of these thyroid transplants to release\nthyroid hormones into the bloodstream. The study confirmed that the\nhuman thyroid tissue transplanted into the Cell Pouch survived and\nreleased human thyroglobulin into the bloodstream, with no adverse\neffects for the three-months duration of\n \n \n the\nstudy.  Thyroglobulin was used as a biomarker efficacy measure in\nthis study as it is the precursor of thyroid hormones.\n \n \n \n \n \n \n “I’m very excited about this study because it represents a\ncritical first step towards a future where we can offer our patients a\ntreatment option that allows...